Open your arms to embrace the future - Health Spring 2024 New Year's party successfully held
Time Posted:2024-01-18 14:21
2023 has come to a successful close, and 2024 quietly unfolds. At the annual meeting, we gathered together, and HealthGen ignited the journey of the new year with joyous reunion. Looking back, HealthGen, with innovation at its core, has achieved success through unity and hard work, resulting in a diversified R&D pipeline. Looking ahead, HealthGen, with patients at its center, will continue to forge ahead on the path of innovation, writing a more glorious new chapter. For health, for tomorrow, we make good medicine with care and dedication.
Time Posted:2023-12-30 11:21
On December 29, 2023, the 2023 Capital Market Crystal Ball Award list, initiated by the Securities Market Weekly, was officially released. HealthGen (600380.SZ) stood out from a number of participating listed companies, winning the "2023 Most Investment Value Listed Company" award, thanks to its core driving force of outstanding independent R&D capabilities.
Healthy Yuan has the appearance of a top Chinese Big Pharma company
Time Posted:2023-12-29 19:12
Needless to say, innovative drugs are the strongest main artery of the long-term operation of China's pharmaceutical industry. After experiencing the capital winter in the primary and secondary markets and the disruption of the epidemic, the "cold adjustment" has brought rationality back to China's innovative drug industry, and the market environment is about to usher in a warm spring as the marginal impact of medical reforms decreases. Under the warm spring, what kind of innovative pharmaceutical companies can win the trend and win the future? Observing the industry, there are many companies that can be listed, each with its own strengths. The industry is also always arguing about the differences and growth of "Biotech", "Biopharma", and "BigPharma". Compared with the mature markets in Europe and the United States, although the number of the most competitive super pharmaceutical companies is an absolute minority, they can influence the direction of the global pharmaceutical market by virtue of their ability to lead industry innovation. Therefore, the rise of China's innovative drug industry will inevitably require a group of seed players who can become super "Big Pharma". Anchoring our observation scope in this way, the listed companies are actually very few.
Time Posted:2023-12-20 17:00
At 23:59 on December 18, a 6.2 magnitude earthquake struck Jishi Mountain County, Linxia Prefecture, Gansu Province, causing serious damage to the local economy and society. When one suffers, all help. Various local governments and public organizations attached great importance to this earthquake and responded quickly to support rescue efforts in the disaster area, providing necessary assistance and support to residents. On the morning of December 20, Healthy Yuan and its subsidiary, Lizhu Group, donated a total of 20 million yuan in rescue funds and medical supplies to the disaster area through the Zhuhai Red Cross Society. This included 10 million yuan in cash and 10 million yuan worth of medicine, to be used for emergency rescue in the affected areas, resettlement of affected people, support for rescue teams, and post-disaster reconstruction.
Time Posted:2023-12-14 15:05
On the morning of December 13, 2023, the 2023 National Medical Insurance Drug Catalog was officially released. Health Yuan's product Jian Ke Tuo® (tobramycin inhalation solution, 5ml: 300mg/vial) has been included in the category B of the National Medical Insurance Catalog. The agreement period is from January 1, 2024 to December 31, 2025.
Time Posted:2023-12-14 13:52
On the morning of December 13, 2023, the 2023 National Medical Insurance Drug Catalog was officially released. HealthGen's product, Jian Ke Tuo® (tobramycin inhalation solution, 5ml: 300mg/vial), was included in Category B of the National Medical Insurance Catalog. The agreement period is from January 1, 2024 to December 31, 2025. This product is suitable for adults with bronchiectasis and lung infection caused by Pseudomonas aeruginosa, controlling infection and improving symptoms. By changing the administration route from intravenous injection to nebulized inhalation, it increases the effective drug concentration in the lungs while reducing systemic toxicity, significantly reducing the risk of drug resistance. It is suitable for long-term maintenance therapy, providing more support for bronchiectasis patients and improving their quality of life. It is understood that there are approximately 20 million patients with bronchiectasis in China, with a prevalence of about 1.2% in people over 40 years old, yet there are no targeted drugs available. To address the high prevalence of bronchiectasis and the lack of clinical drugs in China, HealthGen specially developed an improved new drug—Jian Ke Tuo® (tobramycin inhalation solution). This product was approved for marketing last October. It is the world's first inhaled drug for the treatment of bronchiectasis and the first inhaled antibiotic in China, breaking the situation where inhaled antibiotic treatment was blank in China.
Time Posted:2023-12-09 16:59
With the increasing global focus on sustainable and green development, it has become a consensus for excellent enterprises to practice ESG principles. Consequently, ESG ratings are gradually becoming an important measure in investment evaluation systems. According to recent data from the China Securities Index ESG rating, over 250 companies have seen their ESG ratings improve in 2022. As an innovative and research-oriented comprehensive pharmaceutical group, Health and Wellness (600380.SH) has also recently received a AAA rating from the China Securities Index ESG rating, further attracting market attention.
The Top 100 Chinese Pharmaceutical Companies of 2022 Announced, with Health Spring Among the Top 100
Time Posted:2023-11-21 16:57
On November 17, 2023, the highly anticipated "2023 China Pharmaceutical Industry Development Conference" was held in Beijing, the capital. The event was jointly hosted by the Ministry of Industry and Information Technology, the Beijing Municipal People's Government, the National Health Commission, the State-owned Assets Supervision and Administration Commission of the State Council, the State Administration of Traditional Chinese Medicine, and the National Medical Products Administration. At the conference, the highly anticipated 2022 China Pharmaceutical Industry Top 100 list was released, with Healthy Yuan and Lizhu Group ranking 65th and 21st respectively.